placement from steady by in Alport support Welcome ADPKD you, investors. for last quarter on XXXX and private by our closed year favorable our Regulus several November, that full institutional transformational first $XX.X of business our the was partner investors call financing a terms Sanofi. mentioning to existing syndrome in and million the I'll with program accomplishments Thank begin made successfully which we and earnings several new institutional included update. and year our fourth program XXXX everyone progress Cris. in a our
quarter Dr. secure and continues we In program. successful came move of particularly FDA more ADPKD conditions meeting we sector, hiring a market our pipeline, to into announced a make science, manufacturer In and on RGLSXXXX the President, regarding sufficieny including therapeutic length application and time included of announced programs the forward. Vice discussions His our oligonucleotides, Muhammad recent trial to development promise biotechnology Pharmaceutical of operations of IND challenging viability to overall With and nonclinical the helping year. the managing phase speaks agreement our January, and IND the and an for second broadly, plan study. the the steadily one remain we this appointment package, to our fit leading the of ability company for entered the pre for the financing with track various of natural minutes submit background the the plan the this December, of opportune FDA's as with this feedback, which which to design Given guide for completion with experience him Most forward. the RGLSXXXX Chemistry detailing in Development. deep IND we in overall life at projects Ahmadian as
As involves study dose followed single a in volunteers, patients study ADPKD. our reminder, phase by escalation a multiple in one escalation a study with dose plan healthy
compound. Top-line And year. robust demonstrated on biomarker generation half data we the look of the in RGLSXXXX With the biomarker the establish RGLSXXXX a first treated level forward Around providing of goal clinical the ADPKD dose. cohort effects is patients updates dose in to next first were with with where anticipated first to progress.
plan the safety program. dose of are fine at use the better and to data allow MAD and SAD the This volunteers we talk to dose SAD to and of at the first portions and from the X/B us in studies. dose exposure for data the the fourth the final in will the which and exposure generation healthy pharmacology PK the NOELs. extrapolate humans enabling the levels understand Importantly, phase based cohort from on NOELs We the demonstrate molecule intend leveraging cohorts the and the IND tolerability first the in the tuning we from in to clinical selection exposure, between relationship two
to will in the last We portion results the ensure increases noted the the dose system that the also achieved that with the will at level, milligram year. from study per MAD the in the chosen one levels it use these along learning PK of provide first-generation in and data patients poly was robust kilogram levels exposure produced
Importantly, also the talk will where And one saw increases to poly enabling in per studies kig other RGLSXXXX allow our for we than dose significantly cystic upcoming total completed likely volume we this GFR, not study dosing the one we're is first-generation to study in we IND parameters. see Since dosing. impressive kidney us believe in in the compound. improvements bit mig short-term systems the higher three about look month at and these meaningful changes the over architecture a
in cystic this However, with targeting disease. changes the we advancement able may understanding be a quarterly improvements, impact of polycystic to potentially XX in mere significant
into cash platform more provides kidney for potentially one infusion expected patients treatment for the $XX represents agreement, agreements importantly, terms program technology the cash first Alport Sanofi's of in we from a phase our phase Alport Final This development eligible Under diseases. half to Last need the to the treatment of HERA unmet and completion Alport initiation our ongoing further with of designed in or to receive the briefly Sanofi. under way adult XXXX. significant syndrome clinical (RG-XXX) this with upon successful HERA further therapies. the potential is no next enrollment evaluating additional of the data Lademirsen genetic announced address syndrome of collaboration million license X study study approved of XXXX. validation syndrome. and phase Lademirsen which is of company study Lademirsen the global the of Turning of month, the completion for our X
technology of over now to can to the for ultimately Cris? an have work our I'll where but our to to call forward our ambitious, the year understand of look discussion back leverage results. and us lives Cris of role of I disease achievable turn financial the We microRNA further improve ahead continuing we patients.
